MABTHERA 500 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

mabthera 500 mg

roche pharma ag - germania - rituximabum - conc. pt. sol. perf. - 10mg/ml - anticorpi monoclonali si conjugati anticorp medicament

MABTHERA 1400 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

mabthera 1400 mg

roche pharma ag - germania - rituximabum - sol. inj. - 120mg/ml - anticorpi monoclonali si conjugati anticorp medicament

MABTHERA 1600 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

mabthera 1600 mg

roche pharma ag - germania - rituximabum - sol. inj. - 120mg/ml - anticorpi monoclonali si conjugati anticorp medicament

RIXATHON 100 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

rixathon 100 mg

sandoz gmbh - austria - rituximabum - conc. pt. sol. perf. - 100mg - anticorpi monoclonali si conjugati anticorp medicament

RIXATHON 500 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

rixathon 500 mg

sandoz gmbh - austria - rituximabum - conc. pt. sol. perf. - 500mg - anticorpi monoclonali si conjugati anticorp medicament

RUXIENCE 100mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

ruxience 100mg

pfizer manufacturing belgium nv - belgia - rituximabum - conc. pt. sol. perf. - 100mg - anticorpi monoclonali si conjugati anticorp medicament

RUXIENCE 500mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

ruxience 500mg

pfizer manufacturing belgium nv - belgia - rituximabum - conc. pt. sol. perf. - 500mg - anticorpi monoclonali si conjugati anticorp medicament

TRUXIMA 100 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

truxima 100 mg

millmount healthcare ltd. - irlanda - rituximabum - conc. pt. sol. perf. - 100mg - anticorpi monoclonali si conjugati anticorp medicament

TRUXIMA 500 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

truxima 500 mg

millmount healthcare ltd. - irlanda - rituximabum - conc. pt. sol. perf. - 500mg - anticorpi monoclonali si conjugati anticorp medicament

Riximyo Uniunea Europeană - română - EMA (European Medicines Agency)

riximyo

sandoz gmbh - rituximab - lymphoma, non-hodgkin; arthritis, rheumatoid; microscopic polyangiitis; wegener granulomatosis - agenți antineoplazici - riximyo is indicated in adults for the following indications:non-hodgkin’s lymphoma (nhl)riximyo is indicated for the treatment of previously untreated adult patients with stage iii-iv follicular lymphoma in combination with chemotherapy. riximyo maintenance therapy is indicated for the treatment of adult follicular lymphoma patients responding to induction therapy. riximyo monotherapy is indicated for treatment of adult patients with stage iii-iv follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy. riximyo is indicated for the treatment of adult patients with cd20 positive diffuse large b cell non-hodgkin’s lymphoma in combination with chop (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy. riximyo in combination with chemotherapy is indicated for the treatment of paediatric patients (aged ≥ 6 months to < 18 years old) with previously untreated advanced stage cd20 positive diffuse large b-cell lymphoma (dlbcl), burkitt lymphoma (bl)/burkitt leukaemia (mature b-cell acute leukaemia) (bal) or burkitt-like lymphoma (bll). chronic lymphocytic leukaemia (cll)riximyo in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia. sunt disponibile doar date limitate privind eficacitatea și siguranța pentru pacienții tratați anterior cu anticorpi monoclonali inclusiv rituximab sau pacienții refractari la anterior cu rituximab plus chimioterapie. a se vedea secțiunea 5. 1 pentru informații suplimentare. rheumatoid arthritisriximyo in combination with methotrexate is indicated for the treatment of adult patients with severe active rheumatoid arthritis who have had an inadequate response or intolerance to other disease-modifying anti-rheumatic drugs (dmard) including one or more tumour necrosis factor (tnf) inhibitor therapies. rituximab a fost demonstrat de a reduce rata progresiei distrucției articulare prin x-ray și de a îmbunătăți funcția fizică, atunci când este administrat în asociere cu metotrexat. granulomatosis with polyangiitis and microscopic polyangiitisriximyo, in combination with glucocorticoids, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (wegener’s) (gpa) and microscopic polyangiitis (mpa). riximyo, in combination with glucocorticoids, is indicated for the induction of remission in paediatric patients (aged ≥ 2 to < 18 years old) with severe, active gpa (wegener’s) and mpa. pemphigus vulgarisriximyo is indicated for the treatment of patients with moderate to severe pemphigus vulgaris (pv).